Agoracom Blog Home

Posts Tagged ‘$TSXV’

Peeks Social $PEEK.ca Launches Brand Advertising Program

Posted by AGORACOM-JC at 8:25 AM on Friday, October 20th, 2017

Peeks large

  • As part of the ongoing advancement of the Peeks Social service, an advertising platform integration is now complete
  • Peeks Social ad platform was purpose built to facilitate the sale of all ad units available for sale on broadcast and digital platforms

TORONTO, Oct. 20, 2017 — Peeks Social Ltd. (TSX-V:PEEK) (OTCQB:PKSLF) (“Peeks Social” or the “Company”) is pleased to announce that as part of the ongoing advancement of the Peeks Social service, an advertising platform integration is now complete. The Peeks Social ad platform was purpose built to facilitate the sale of all ad units available for sale on broadcast and digital platforms.  Specifically, the Peeks Social ad platform facilitates the sale of product placement ads, cost per impression (“CPM”) ads, cost per action (“CPA”) ads, onscreen overlays, and affiliate marketing programs.

The Peeks Social ad platform interacts with the OfferBox so that ads can result in direct sales. The Peeks Social proprietary ad platform allows advertisers to target ads based on a wide variety of viewer demographics including location, age, gender, and individual tastes.

The platform will be launching multiple ad campaigns through aggregate and direct brand partners ranging from in-stream sponsors, CPM, and CPA advertisers.  Some of the brands and offers that will be available include eHarmony, Fandango DermaVia, Namaste, and others.

As previously announced on September 14, 2017, the Company has now released two of three new advertising and sales features and is on schedule to release the final component of the full OfferBox alongside 50+ brands that will be available to streamers on the Peeks Social service upon release. This will include brands that are participating in paid advertising campaigns.

Stock Option Grant

The Company also announced that in accordance with the Company’s Stock Option Plan, it has granted 500,000 options to Board Member Jim Westlake, and 75,000 options to Director of Investor Relations David Vinokurov.  The options vest over a 12-month period as to 20% immediately and 20% every three months thereafter.  The options are exercisable at $0.60 and expire five years from the date of grant.

For further information, please contact:

Peeks Social Ltd.                   Mark Itwaru       David Vinokurov Chairman & Chief Executive Officer        Director Investor Relations 647-992-7727       416-716-9281  [email protected]        [email protected]
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has reviewed or accepts responsibility for the adequacy or accuracy of this Release.

Forward-Looking statements:

The information and statements in this news release contain certain forward-looking information relating to the development, functionality, and deployment of certain functionalities of the Peeks Social livestreaming product, including assumptions regarding third party adoption and use. This forward-looking information is subject to certain risks and uncertainties and may be based on assumptions that could cause actual results to differ materially from those anticipated or implied in the forward-looking information. Peeks Social Ltd.’s forward-looking information is expressly qualified in its entirety by this cautionary statement. Except as required by law, Peeks Social Ltd. undertakes no obligation to publicly update or revise any forward-looking information.

Tartisan Resources Corp. $TTC.ca to Acquire Canadian Arrow Mines Limited $CRO.ca

Posted by AGORACOM-JC at 8:11 AM on Friday, October 20th, 2017

Tartisan logo copy

  • Tartisan will acquire all of the issued and outstanding common shares of Canadian Arrow Mines Limited by way of a court-approved plan of arrangement
  • Tartisan would issue to Canadian Arrow Mines Limited shareholders one common share of Tartisan for every 17.5 common shares of Canadian Arrow, resulting in the issuance of approximately 8,000,000 common shares of Tartisan

TORONTO, Oct. 20, 2017 – Canadian Arrow Mines Limited (TSX.V:CRO) – (“Canadian Arrow”) announces that a definitive arrangement agreement (the “Agreement”) has been signed with Tartisan Resources Corp. (CSE: TTC) – (“Tartisan”) whereby Tartisan will acquire all of the issued and outstanding common shares of Canadian Arrow Mines Limited (“Canadian Arrow”) by way of a court-approved plan of arrangement (the “Arrangement”) in accordance with the Business Corporations Act (Ontario) in exchange for common shares in the capital of Tartisan.

Pursuant to the terms of the Agreement, Tartisan would issue to Canadian Arrow Mines Limited shareholders one common share of Tartisan for every 17.5 common shares of Canadian Arrow, resulting in the issuance of approximately 8,000,000 common shares of Tartisan. Additionally, Tartisan would issue up to 4,500,000 common shares of Tartisan to settle Canadian Arrow debt pursuant to debt conversion agreements with various Canadian Arrow creditors. Certain lock up provisions are included in the Debt Conversion Agreements. Tartisan has also agreed to pay the transaction related expenses of Canadian Arrow.

The proposed transaction provides Canadian Arrow shareholders with liquidity, sustaining capital and an opportunity to participate in the potential upside of Tartisan.

The board of directors of Canadian Arrow (the “Canadian Arrow Board”) has approved the Arrangement and the entering into of the Arrangement Agreement and has determined to recommend that shareholders of Canadian Arrow vote in favour of the Arrangement. Completion of the Arrangement is subject to customary closing conditions, including approval of the Ontario Superior Court of Justice (Commercial List), the approval of holders of not less than 66 2/3% of the holders of Canadian Arrow Shares voted at a special meeting of Canadian Arrow shareholders that will be called to approve the Arrangement (the “Special Meeting”) as well as majority of the minority approval as required under applicable Canadian securities laws. The Arrangement is also subject to the approval of the TSX Venture Exchange, the Canadian Securities Exchange and all applicable regulatory authorities, as well other conditions typical for a transaction of this nature.

The terms of the Arrangement will be summarized in an information circular of Canadian Arrow (the “Circular”) that is anticipated to be mailed to the shareholders of Canadian Arrow in connection with the Special Meeting which is expected to be held in early January 2018. Canadian Arrow has received from Harris Capital Corporation an opinion that the Arrangement consideration is fair, from a financial point of view, to the shareholders of Canadian Arrow, and retained Fogler Rubinoff LLP as its legal counsel. Robert M. Isles is acting as legal counsel to Tartisan. A copy of the Arrangement Agreement, the Circular and related documents will be filed with the Canadian regulatory authorities and will be available for review under Canadian Arrow’s SEDAR profile at www.sedar.com.

The Agreement contains customary non-solicitation provisions which are subject to Canadian Arrow’s right to consider and accept a superior proposal subject to a matching right in favour of Tartisan. In the event that the Arrangement is not completed as a result of a superior proposal or for other certain specified circumstances, Canadian Arrow will pay Tartisan a termination fee of $100,000.

The Arrangement constitutes a “business combination” under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”) for Canadian Arrow as Canadian Arrow is indebted to certain of its directors and such indebtedness will be settled through the issuance of common shares of Tartisan in connection with the closing of the Arrangement. The indebtedness of Dean MacEachern is approximately $9,000, the indebtedness of Kim Tyler is approximately $5,000 and the indebtedness of George Pirie is approximately $20,000. Although Canadian Arrow does not consider the amounts of such indebtedness to be material the fact that such indebtedness is being satisfied through the issuance of common shares of Tartisan in connection with the completion of the Arrangement means that the Arrangement is considered to be a Business Combination for the purposes of MI 61-101. Canadian Arrow is relying on the formal valuation exemption in section 4.4(a) of MI 61-101, on the basis that no securities of Canadian Arrow are listed on the Toronto Stock Exchange or other specified markets. Canadian Arrow will seek the requisite approvals of the Arrangement from its shareholders at the Special Meeting.

If the Arrangement is completed, the common shares of Canadian Arrow will be delisted from the TSX Venture Exchange.

None of the securities to be issued pursuant to the Arrangement Agreement have been or will be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and any securities issued in the Arrangement are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act and applicable exemptions under state securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

About Tartisan Resources Corp.

Tartisan Resources Corp. is a Canadian mineral exploration and development company focused on project generation of precious and base metal properties. Tartisan owns a 100% stake in the Don Pancho Zinc-Lead-Silver Project just 9 km from Trevali’s Santander Mine and owns a 100% stake in the Ichuna Copper-Silver Project contiguous to Buenaventura’s San Gabriel Property. Tartisan Resources portfolio also includes an equity stake (6 million shares and 3 million warrants @ 40 cents) in Eloro Resources Ltd. (TSX.V:ELO). Tartisan Resources Corp. common shares are listed on the Canadian Securities Exchange and is a Member of the CSE Composite Index (CSE:TTC). There are currently 73,052,443 shares outstanding (90,145,827 fully diluted).

About Canadian Arrow Mines Limited

Canadian Arrow is an experienced exploration and mine operating team that is focussed on acquiring and developing economically viable nickel sulphide deposits near existing infrastructure. Canadian Arrow operates in north-western Ontario, near the towns of Kenora and Dryden. The company’s main asset is the Kenbridge Nickel Project, a nickel-copper sulphide deposit containing over 98 million lbs of nickel in Measured & Indicated Resources. The deposit is equipped with a 620m shaft and has never been mined.

Additional information about Canadian Arrow can be found at the company’s website at www.canadianarrowmines.com or on SEDAR at www.sedar.com.

Forward Looking Information

Certain information contained in this news release constitutes forward looking information. All information other than information of historical fact is forward looking information. The use of any of the words “intend”, “anticipate”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “would”, “believe”, “predict” and “potential” and similar expressions are intended to identify forward looking information. This information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward looking information. No assurance can be given that this information will prove to be correct and such forward looking information included in this news release should not be unduly relied upon.

The forward looking information provided in this news release is based upon a number of material factors and assumptions including, without limitation: (a) that the Arrangement will be completed in the timelines and on the terms currently anticipated; (b) that all necessary CSE, TSXV, court and regulatory approvals will be obtained on the timelines and in the manner currently anticipated; (c) that all necessary Shareholder approvals will be obtained; and (d) general assumptions respecting the business and operations of both Canadian Arrow and Tartisan, including that each business will continue to operate in a manner consistent with past practice and pursuant to certain industry and market conditions.

Readers are cautioned that the foregoing list of risks, uncertainties and assumptions are not exhaustive.

The forward looking information included in this news release is expressly qualified by this cautionary statement and is made as of the date of this news release. Neither Canadian Arrow nor Tartisan undertake any obligation to publicly update or revise any forward looking information except as required by applicable securities laws.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Canadian Arrow Mines Limited

Tetra Bio-Pharma $TBP.ca Hires Medical Science Liaison to Promote Rx Princeps(TM) and Presents its New Corporate Image

Posted by AGORACOM-JC at 8:07 AM on Thursday, October 19th, 2017

Tbp large new

  • Announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).
  • Will be responsible for the medical information of Rx Princepsâ„¢ and will be educating the medical community about the benefits of this controlled and standardized blend of medical cannabis

OTTAWA, ONTARIO–(Oct. 19, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced the hiring of Dr. Vincent Jourdain, Ph. D. as medical science liaison (MSL).

Dr. Jourdain will be responsible for the medical information of Rx Princepsâ„¢ and will be educating the medical community about the benefits of this controlled and standardized blend of medical cannabis. Dr. Jourdain has extensive training and knowledge in pharmacology and neuroscience and is a critical addition to the Tetra team. An important part of his role will be to support the sales of Rx Princepsâ„¢ through New Brunswick and the Maritimes, as well as in Quebec, by presenting the safety, pharmacokinetic, and pharmacodynamic data gathered in Tetra’s Phase 1 clinical trial of PPP001.

“The addition of Dr. Jourdain demonstrates our strategic intention to position Tetra Bio-Pharma as the leader in the medical cannabis market. Bringing an individual with the level of scientific knowledge and expertise of Dr. Jourdain shows our organization’s commitment to the medical community; they can continue to count on Tetra Bio-Pharma as a credible and professional source of information for their practice and their patients. We are looking forward to further developing relationships with opinion leaders in the field as we continue to advance our clinical program and work on bringing new drug alternatives for patients and their treating healthcare professionals.” states Dr. Guy Chamberland, Chief Scientific Officer of Tetra.

Tetra also reveals today its new logo and corporate image, thereby aligning its corporate image with its medical strategy. The evolution of The Company’s image highlights Tetra’s objective to be the reference for the medical community in prescribed cannabinoids’ safety, efficacy, and quality. Tetra is focused on bringing to the ACMPR market the highest quality medical cannabis; the Company remains committed to receive the first drug approval from Health Canada’s Therapeutic Products Directorate for a medical cannabis drug.

About RxPrincepsâ„¢:

Rx Princepsâ„¢ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princepsâ„¢ is composed of the same medical cannabis blend used to produce PPP001, which has demonstrated its safety in the Phase 1 clinical trial of PPP001.

Rx Princepsâ„¢ will soon be available across Canada, through our partner Aphria’s customer service, for patients who have a prescription from their physicians.

About Dr. Vincent Jourdain, Ph.D.:

Dr. V. Jourdain, Ph.D. is a graduate from the pharmacy program at Laval University in Quebec City, where he specialized in neurological disorders. He completed his postdoctoral training at the Feinstein Institute for Medical Research in New York. He used brain imaging to study metabolic and neurovascular changes in Parkinson’s disease and pharmacologically-induced side effects. Dr. Jourdain possesses a broad, yet specialized, knowledge in Neurology and accumulated close to 10 years of experience in basic and clinical research. He published over 15 peer-review publications and won several awards and scholarships.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
[email protected]
(514) 360-8040 Ext. 210

FEATURE: BetterU $BTRU.ca Focusing on #India, a High-Growth #Edtech Market, to Drive Large Sales with Strategic Partnerships #Adobe $ADBE

Posted by AGORACOM-JC at 4:25 PM on Wednesday, October 18th, 2017

BTRU: TSX-V

CONNECTING GLOBAL EDUCATION WITH THE INDIAN MARKETPLACE

WHY BETTERU EDUCATION?

  • The ONLY Global Education Marketplace Serving India
  • betterU Partners With Adobe to Deliver Leading Digital Experience Programs in India
  • Capitalizing On Mobile Payments Structure Others Unable To Provide
  • Unique Ability To Collect From 200 Different Payment Methods in India
  • As A Result, Leading Global Online Education Providers Use BetterU
  • BetterU Receives 20 – 50% Of All Revenues Generated
  • Indian Government Mandate To Educate 500 million by 2022
  • India Expecting To Double Online Education From $20B to $40B
  • Executed MOU with the Telecom Sector Skill Council to jointly support both organizations’ efforts towards the skilling of millions of professionals across India’s Telecom sector

FEATURE: PyroGenesis $PYR.ca arguably the most advanced plasma technology Company in the world

Posted by AGORACOM-JC at 1:04 PM on Wednesday, October 18th, 2017
PyroGenesis Canada Inc. (TSX-V: PYR) (OTC: PYRNF) (Frankfurt: 8PYF)

  • Arguably the most advanced plasma technology Company in the world, with one of the largest concentration of plasma expertise under one roof working out of a ~40,000 sq. ft. facility in Montreal,
  • Considered the go-to source for the US Military when an application requires a plasma solution, it has over 57 patents (issued or pending), including being the inventors of ‘plasma atomization’ which is considered the current gold standard for production of Titanium-metal powder used in additive manufacturing (3D printers).
  • Company’s latest innovations/plasma solutions in chemical warfare agent destruction, metallurgy, and especially additive manufacturing, are all revolutionary, each on the cusp of exponential growth, and position the share price of PYR.V at a major inflection point, presenting opportunity for astute shareholders.

Click here to read entire feature.

Monarques Gold $MQR.ca buys back royalty on the Wasamac property from Globex $GMX.ca

Posted by AGORACOM-JC at 10:30 AM on Wednesday, October 18th, 2017

Monarquesgold hub large

  • Announced that Globex Mining Enterprises Inc. has purchased the 1.5% Net Smelter Royalty (NSR) applicable to Globex’s wholly-owned Francoeur/Arntfield gold property
  • As consideration for the royalty, Globex made a $25,000 cash payment to Monarques and cancelled a 0.5% NSR payable by Monarques to Globex on 11 claims located on the eastern portion of Monarques’ Wasamac gold property

MONTREAL, Oct. 18, 2017 – MONARQUES GOLD CORPORATION (“Monarques” or the “Corporation”) (TSX-V: MQR) (FRANKFURT: MR7) is pleased to announce that Globex Mining Enterprises Inc. (“Globex”) (TSX: GMX) has purchased the 1.5% Net Smelter Royalty (NSR) applicable to Globex’s wholly-owned Francoeur/Arntfield gold property. As consideration for the royalty, Globex made a $25,000 cash payment to Monarques and cancelled a 0.5% NSR payable by Monarques to Globex on 11 claims located on the eastern portion of Monarques’ Wasamac gold property. In addition, Globex has extended Monarques’ right to store Wasamac core at Globex’s Francoeur Mine site to June 30, 2019.

“As part of our strategy to control costs, this agreement will reduce any future royalty payments on our Wasamac property,” said Jean-Marc Lacoste, President and Chief Executive Officer of Monarques. “The agreement also allows us to lock in short-term cash on the Globex royalty and savings for our Wasamac project.”

ABOUT MONARQUES GOLD CORPORATION

Monarques Gold Corp (TSX-V: MQR) is an emerging gold producer focused on pursuing growth through its large portfolio of high-quality projects in the Abitibi mining camp in Quebec, Canada. The Corporation currently owns more than 240 km² of gold properties (see map), including the Beaufor Mine, the Croinor Gold (see video) and Wasamac advanced projects, and the Camflo and Beacon mills, as well as six promising exploration projects. It also offers custom milling services out of its 1,200 tonne-per-day Camflo mill. Monarques enjoys a strong financial position and has more than 150 skilled employees who oversee its operating, development and exploration activities.

Forward-Looking Statements

The forward-looking statements in this press release involve known and unknown risks, uncertainties and other factors that may cause Monarques’ actual results, performance and achievements to be materially different from the results, performance or achievements expressed or implied therein. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Monarques Gold Corporation

$GR.ca Great Atlantic Drills Keymet Base Metal Project, Newfoundland

Posted by AGORACOM at 9:00 AM on Wednesday, October 18th, 2017

  • Keymet is a past producing Pollymetallic property
  • Hole Ky-17-6 included 50M of arsenopyrite which has traditionally carried gold at Keymet
  • Pollymetallic mines are the most sought after Base Metal projects due to presence of multiple ore types

Vancouver, British Columbia (FSCwire)GREAT ATLANTIC RESOURCES CORP. (TSXV.GR) (the “Company” or “Great Atlantic”) is pleased to announce it has completed a diamond drilling program at its Keymet Precious – Base Metal Property, located near Bathurst, northeast New Brunswick. The Keymet property hosts multiple gold, silver, zinc, lead and / or copper occurrences and the Keymet deposit, site of the historic Keymet Mine. The drilling program (5 holes totalling 679 meters) was conducted in the northwest region of the property, northwest of the historic Keymet Mine.

 

“We are very encourage at this year’s drill program and are enthusiastically awaiting all the results but particularly interested in the unexpected arsenopyrite within a 50 meter core length interval in hole Ky-17-6, traditionally arsenopyrite has carried Gold on this property.  As well we want to say a special thanks to Don and the guys at Orbit Garant Drilling, excellent job “Says: Christopher R Anderson CEO

 

To view the graphic in its original size, please click here

 

The program tested the continuation of zinc, copper and silver bearing veins and a gold mineralization intersected by Great Atlantic during 2015 diamond drilling and trenching programs. All five holes intersected veins hosting base metal sulfides while three holes also intersected arsenopyrite mineralization. Gold mineralization on the property is associated with arsenopyrite.  The Company is conducting systematic sampling of mineralized drill core from the recent program.

 

Gold bearing boulders (samples up to 51 grams / tonne (g/t) Au) and gold bearing bedrock in trenches and drill core have been discovered by Great Atlantic in the northwest region of the property. Great Atlantic drilled two holes in 2015 at one site in this region (Ky-15-3 and Ky-15-4), approximately 1.4 kilometers of the historic Keymet Mine, in an area referred to as the Elmtree 12 occurrence. Both 2015 holes intersected base metal and silver bearing veins (including 16.68% zinc, 1.11% copper and 152.0 g/t silver over 1.80 metre core length in Ky-15-3 and 8.68% zinc and 44.8 g/t silver Ag over 4.28 metre core length in Ky-15-4). Hole Ky-15-3 also intersected a gold bearing interval (3.28 g/t Au over 2.1 meter core length). The true width of these initial 2015 drill intersections is unknown at this time. The recent drilling tested the continuation of this base metal and precious metal mineralization.

 

To view the graphic in its original size, please click here

 

Each of the 2017 drill holes intersected veins with copper, lead and zinc sulfide mineralization. Arsenopyrite mineralization has been observed in three of these holes. Gold mineralization in boulders and bedrock in this area is associated with arsenopyrite.

 

Holes Ky-17-5, 6, 7 and 9 of the recent program were drilled in the same area as 2015 holes Ky-15-3 and 4. Each of these four holes intersected base metal bearing veins. Company management are interpreting the main veins to be within a steep dipping to vertical vein system to strike approximately north – south, with all Great Atlantic drill intersections to date being within an approximately 70 meter strike length and shallow (above 100 meter vertical depth).  Hole Ky-17-6 intersected local arsenopyrite within an approximate 50 meter core length interval appearing to be east to northeast of the main base metal bearing vein zone.  Holes Ky-17-5 and 7 also intersected local arsenopyrite.

 

To view the graphic in its original size, please click here

 

To view the graphic in its original size, please click here

Veins containing copper, zinc and lead sulfide mineralization in hole Ky-17-07

 

To view the graphic in its original size, please click here

Vein containing copper and zinc sulfide mineralization in hole Ky-17-05.

 

To view the graphic in its original size, please click here

Vein containing zinc and lead sulfide mineralization in hole Ky-17-8

 

Hole Ky-17-8, located approximately 80 meters southwest of holes Ky-17-5, 6 and 7, tested the down-dip extension of a gold bearing zone discovered by the Company in a 2015 trench (channel samples returning 1.1 g/t Au over 4.9 meters). The gold bearing zone in the trench is characterized by minor arsenopyrite in metasediments and increased quartz veining. A fault zone is also exposed in the trench hosting base metal and silver mineralization (2015 grab sample returned 8.99% lead, 1.76% zinc, 0.80% copper and 237 g/t silver). Arsenopyrite is not apparent in Ky-17-8 drill core. However quartz veining was intersected under the trench gold zone. The hole also intersected veins with base metal sulfides approximately vertically under the trench fault zone.

 

Closed-spaced 1980s diamond drill holes (Brunswick Mining and Smelting and Aurtec Inc.) in the area of holes Ky-15-3, 4, Ky-17-5, 6, 7 and 9 intersected near-surface mineralized veins (Elmtree 12 vein occurrence). A 0.88 metre core length interval from a 1981 drill hole was reported to grade 7.72% Cu, 11.36% Zn an 13.6 ounces per ton Ag. A 1.22 metre core length sample from a near-by 1989 drill hole was reported to assay 16.4% Cu, 10.11% Zn and 31.0 ounces per ton Ag. The true width of these intersections is unknown. These drill intersections are within 50 metre vertical depth. Great Atlantic personnel found loose casing in this area during 2015. It is uncertain which historic hole this represents.

 

Access to the property is excellent with paved roads transecting the property, including a provincial highway. The property covers an area of approximately 3,400 hectares.

 

To view the graphic in its original size, please click here

 

Readers are warned that historical records referred to in this News Release have been examined but not verified by a qualified person. Further work is required to verify that historical assays referred to in this News Release are accurate.

 

David Martin, P.Geo., a Qualified Person as defined by NI 43-101, is responsible for the technical information contained in this News Release.

 

About Great Atlantic Resources Corp.: Great Atlantic Resources Corp. is a Canadian exploration company focused on the discovery and development of mineral assets in the resource-rich and sovereign risk-free realm of Atlantic Canada, one of the number one mining regions of the world. Great Atlantic is currently surging forward building the company utilizing a Project Generation model, with a special focus on the most critical elements on the planet that are prominent in Atlantic Canada, Antimony, Tungsten and Gold.

 

 

Tetra Bio-Pharma $TBP.ca Signs Agreement with Partner Aphria $APH.ca to Start Promoting Rx Princeps(TM), its Medical Cannabis Blend, under ACMPR

Posted by AGORACOM-JC at 8:12 AM on Wednesday, October 18th, 2017

Tbp large new

  • Will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR)
  • Signed a distribution agreement with its trusted partner Aphria to sell Rx Princepsâ„¢, its unique blend of dried medical cannabis used in its PPP0001 clinical trials

OTTAWA, ONTARIO- (Oct. 18, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, today announced that it will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regulations (ACMPR). Tetra has signed a distribution agreement with its trusted partner Aphria to sell Rx Princepsâ„¢, its unique blend of dried medical cannabis used in its PPP0001 clinical trials. Production of Rx Princeps has been initiated and will be available to patients in the coming weeks.

Rx Princepsâ„¢ will be a new option for doctors who want to prescribe medical cannabis, while ensuring that their patients will receive a consistent and high-quality product. Aphria grows and produces medical cannabis under a strict quality management program. Tetra chose Aphria as its partner because their production processes were adopted from the highly restricted and regulated pharmaceutical industry, and go above and beyond cannabis industry regulations mandated by Health Canada, thereby complying with the quality standards Tetra wants to bring to the medical community and its patients.

Rx Princepsâ„¢ will be a new therapeutic option not only for the 19% of adults who suffer from chronic pain in Canada, but also for the more than 200,000 patients already registered under the ACMPR program. Based on the most recent ACMPR market data from the Government of Canada, it is estimated that the sales of dried medical cannabis in Canada from April 2017 to March 2018 will be over $188M; Tetra is now prepared to enter this lucrative market.

“Our objective is to position ourselves as the reference for the medical community in the prescription of medical cannabis, and gain our growing share of that market in the years to come. We believe that we are bringing additional value to patients, physicians and other key healthcare professionals involved in treating at-need patients. We are ready to launch our first medical product, and we couldn’t be more pleased to do it with a partner such as Aphria, which has demonstrated their commitment to our vision of offering a medical product of the highest quality. Our team is dedicated to make this part of our business a very successful one, bringing value to our investors in the process. Being able to generate revenue to support our operations is an important step for Tetra Bio-Pharma,” says Bernard Fortier, CEO of Tetra Bio-Pharma.

About Rx Princepsâ„¢:

Rx Princepsâ„¢ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princepsâ„¢ is composed of the same medical cannabis blend used to produce PPP001, which has demonstrated its safety in the Phase 1 clinical trial of PPP001.

Rx Princepsâ„¢ will be available across Canada, through Aphria’s customer service, for patients who have a prescription from their physicians.

About Aphria:

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information about Aphria, please contact:
Nina Godard – Edelman
416-455-6324
[email protected]

Vic Neufeld, President & CEO
1-844-427-4742

For further information about Tetra Bio-Pharma
and Rx Princeps(TM), please contact Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
[email protected]

#Palladium Price Hits 16-Year High #PGM $NAM.ca

Posted by AGORACOM-JC at 2:47 PM on Tuesday, October 17th, 2017
October 17, 2017  by SchiffGold

A UBS strategist told CNN she’s convinced palladium’s strength is driven by fundamentals.

Like silver, palladium has both industrial and investment value. It is used in cars, electronics, dentistry, and jewelry. Between 1988 and 2002, the Canadian mint produced a palladium Maple Leaf coin.

Commerzbank analysts talked up palladium in a note to its clients.

Palladium is continuing to soar. Not only does demand from the automotive industry appear robust — speculative financial investors are also remaining loyal to palladium.”

Analysts say the surge in the price of palladium is due to strong demand for the metal, coupled with tight supply. About 78% of the demand comes from the auto industry. The metal is used in catalytic converters for gasoline-powered engines. The drive to curb auto emissions and the “demise of the diesel engine” in passenger cars has boosted demand for the metal.

According to analysts at City Index, tight supply is the primary factor driving the price of palladium.

Palladium supply is at its lowest level for 14 years and demand has been outpacing supply since 2011.  There is a strong potential for an ongoing supply deficit in the coming months, which could trigger a further price rise.”

Joni Teves, an analyst at UBS, told the Telegraph there is a currently a major shortfall in palladium production. The market could hit a deficit of 830,000 ounces this year, as miners have cut back production due to unproductive mines and increasing mining costs.

Russia and South Africa lead the world in palladium production.

The palladium market’s downside stems from its heavy reliance on the auto industry. Some analysts say the eventual rise of electric vehicles will impact the demand for metals used in catalytic converters. But electronic car technology still appears a long way from mass consumer acceptance. Their lack of range, the need for frequent charging, and their cost makes electric vehicles less than ideal for the average person.

The palladium market is much more volatile than gold and silver, but it could serve as an excellent diversifier for your precious metals portfolio. Call 1-888-GOLD-160 to talk to one of SchiffGold’s precious metals specialists today to learn more about investing in palladium.

Source: https://schiffgold.com/key-gold-news/palladium-price-hits-16-year-high/

FEATURE: Augusta Industries $AAO.ca Discusses Spin-Out Transaction, Clients of Subsidiaries include: #Enbridge $ENF.ca #Shell $RDS #Chevron $CVX #NASA

Posted by AGORACOM-JC at 1:28 PM on Tuesday, October 17th, 2017

Augustalarge

 

Augusta Industries (AAO:TSXV) is a superstar company that very few people small cap investors have ever heard of. More than just lip service, take a quick look at the client rolls of their 2 subsidiaries. Once you do, you’ll understand why Augusta just announced a spin out transaction that will split the subsidiaries into two companies, making shareholders very happy.

SUBSIDIARIES

1]  FOX-TEK – World leading solutions to various sectors including the oil and gas industry. With non- intrusive technologies including: fiber optic sensors and electric field mapping systems; FOX-TEK is able to accurately measure changes that could negatively impact clients’ operations, the list of which includes the following Tier-1 Energy Companies.

2]  Marcon International – an industrial supply contractor servicing the energy sector and a number of US Government entities. Marcon’s principal business is the sale and distribution of industrial parts and equipment to clients that include government departments and global energy companies.

  • Aiming to deliver $25M in additional shareholder value with its Sensor Technologies spin out announcement on September 28th.
  • At the time of “Spin out”, Augusta will own 50 Million shares of Sensor Tech, and 100% of Marcon International,
  • Transaction unleashing the potential for explosive growth through its multinational relationships and state of the art monitoring technology

Augusta is a burgeoning beast in the Oil & Gas service sector with its multi-faceted approach to creating shareholder value for its shareholders.

WATCH OUR RECENT INTERVIEW